Cyn- welcome back!! As one of the cheeky fella's keeping things light with golf and horse racing analogies, I'm not certain the context of that comment as it pertains to the rest of your post.
I read all of your posts and just went back to read yours over the the last three weeks. The one post you may be referring to may not be the same one I think you're referring to. Out of respect, I'm not posting the Post number but why don't you. It's out there and too many times we get cute with the "teasing" of info that may or may not be accurate.
With that said, here's my "prediction". This company will be sold. I believe that Nader made the comment about the timelines going into 2018 to show he has the means and patience to take this to market and COMPETE with the big boys. Also, the partnership with the company announced the other day was a prudent insurance policy to keep things moving forward. Carrociola is in charge behind the scenes and they're not going to tip their hand by telling the world they want to sell. We have a groundbreaking product in PRO140, which gives the leadership options!
If someone wants it bad enough, they'll pay. If not, Carrociola has a contingency plan. Until this drug is on an "assembly line", that partnership agreement is nothing but gamesmanship!
Final Prediction: once and if BTD is approved, another run should sustain. We need to get to $1 and hold there. As ODD and adjunct become more of a reality, the price goes up, but it goes up exponentially at each milestone.
People can criticize Nader all they want but being an executive who has had to bite their tongue while wild predictions are made and untruths spoken, all the time knowing people don't know what they're talking about can be taxing. I bought in three months ago and I haven't seen Nader make a bad move yet!
Cyn- I hope I'm on the right track here
News 
Market Data 
Discover 
